EP Patent

EP3651734C0 — COMPOSITIONS CONTAINING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRUS INFECTIONS

Assigned to Gilead Sciences Inc · Expires 2024-11-13 · 2y expired

What this patent protects

Patent listed against Veklury.

Drugs covered by this patent

Veklury (remdesivir) · Gilead Sciences

Patent Metadata

Patent number: EP3651734C0
Jurisdiction: EP
Classification: —
Expires: 2024-11-13
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.